Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical

Carla J. Mathias, Susan Wang, David J. Waters, John J. Turek, Philip S. Low, Mark Green

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

Indium-111-labeled diethylenetriamine pentaacetic acid (DTPA)-folate was evaluated as a radiopharmaceutical for targeting tumor-associated folate receptors. Methods: Athymic mice were subcutaneously inoculated with ~1.8 x 106 folate receptor-positive KB (human nasopharyngeal carcinoma) cells, yielding 0.2- to 0.6-g tumors in 15 days, at which time 111In-DTPA- folate, 111In-DTPA or 111In-citrate was administered by intravenous injection. Results: The 111In-DTPA-folate conjugate afforded marked tumor- specific 111In deposition in vive using this mouse model. The involvement of the folate receptor in mediating tumor uptake of 111In-DTPA-folate was demonstrated by the blocking of tumor uptake by coadministration of free relic acid (intravenous). The 111In-DTPA-folate also shows folate receptor-mediated uptake and retention in the kidneys, presumably reflecting radiotracer binding to folate receptors of the proximal tubules. In control experiments, the 111In-citrate radiopharmaceutical precursor was also shown to afford significant tumor uptake of 111In, but with much poorer tumor-to-background tissue contrast than that obtained with 111In-DTPA- folate. Unconjugated 111In-DTPA showed no tumor affinity. Conclusion: Indium-111-DTPA-folate appears suitable as a radiopharmaceutical for targeting tumor-associated folate receptors.

Original languageEnglish (US)
Pages (from-to)1579-1585
Number of pages7
JournalJournal of Nuclear Medicine
Volume39
Issue number9
StatePublished - Sep 1998
Externally publishedYes

Fingerprint

Pentetic Acid
Indium
Radiopharmaceuticals
Folic Acid
Neoplasms
Citric Acid
Nude Mice
Intravenous Injections

Keywords

  • Folate receptor
  • Indium-111-diethylenetriamine pentaacetic acid folate
  • Tumor targeting

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Mathias, C. J., Wang, S., Waters, D. J., Turek, J. J., Low, P. S., & Green, M. (1998). Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. Journal of Nuclear Medicine, 39(9), 1579-1585.

Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. / Mathias, Carla J.; Wang, Susan; Waters, David J.; Turek, John J.; Low, Philip S.; Green, Mark.

In: Journal of Nuclear Medicine, Vol. 39, No. 9, 09.1998, p. 1579-1585.

Research output: Contribution to journalArticle

Mathias, CJ, Wang, S, Waters, DJ, Turek, JJ, Low, PS & Green, M 1998, 'Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical', Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1579-1585.
Mathias, Carla J. ; Wang, Susan ; Waters, David J. ; Turek, John J. ; Low, Philip S. ; Green, Mark. / Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical. In: Journal of Nuclear Medicine. 1998 ; Vol. 39, No. 9. pp. 1579-1585.
@article{740fbb0b40814418b0789a31f1f6d306,
title = "Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical",
abstract = "Indium-111-labeled diethylenetriamine pentaacetic acid (DTPA)-folate was evaluated as a radiopharmaceutical for targeting tumor-associated folate receptors. Methods: Athymic mice were subcutaneously inoculated with ~1.8 x 106 folate receptor-positive KB (human nasopharyngeal carcinoma) cells, yielding 0.2- to 0.6-g tumors in 15 days, at which time 111In-DTPA- folate, 111In-DTPA or 111In-citrate was administered by intravenous injection. Results: The 111In-DTPA-folate conjugate afforded marked tumor- specific 111In deposition in vive using this mouse model. The involvement of the folate receptor in mediating tumor uptake of 111In-DTPA-folate was demonstrated by the blocking of tumor uptake by coadministration of free relic acid (intravenous). The 111In-DTPA-folate also shows folate receptor-mediated uptake and retention in the kidneys, presumably reflecting radiotracer binding to folate receptors of the proximal tubules. In control experiments, the 111In-citrate radiopharmaceutical precursor was also shown to afford significant tumor uptake of 111In, but with much poorer tumor-to-background tissue contrast than that obtained with 111In-DTPA- folate. Unconjugated 111In-DTPA showed no tumor affinity. Conclusion: Indium-111-DTPA-folate appears suitable as a radiopharmaceutical for targeting tumor-associated folate receptors.",
keywords = "Folate receptor, Indium-111-diethylenetriamine pentaacetic acid folate, Tumor targeting",
author = "Mathias, {Carla J.} and Susan Wang and Waters, {David J.} and Turek, {John J.} and Low, {Philip S.} and Mark Green",
year = "1998",
month = "9",
language = "English (US)",
volume = "39",
pages = "1579--1585",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - Indium-111-DTPA-folate as a potential folate-receptor-targeted radiopharmaceutical

AU - Mathias, Carla J.

AU - Wang, Susan

AU - Waters, David J.

AU - Turek, John J.

AU - Low, Philip S.

AU - Green, Mark

PY - 1998/9

Y1 - 1998/9

N2 - Indium-111-labeled diethylenetriamine pentaacetic acid (DTPA)-folate was evaluated as a radiopharmaceutical for targeting tumor-associated folate receptors. Methods: Athymic mice were subcutaneously inoculated with ~1.8 x 106 folate receptor-positive KB (human nasopharyngeal carcinoma) cells, yielding 0.2- to 0.6-g tumors in 15 days, at which time 111In-DTPA- folate, 111In-DTPA or 111In-citrate was administered by intravenous injection. Results: The 111In-DTPA-folate conjugate afforded marked tumor- specific 111In deposition in vive using this mouse model. The involvement of the folate receptor in mediating tumor uptake of 111In-DTPA-folate was demonstrated by the blocking of tumor uptake by coadministration of free relic acid (intravenous). The 111In-DTPA-folate also shows folate receptor-mediated uptake and retention in the kidneys, presumably reflecting radiotracer binding to folate receptors of the proximal tubules. In control experiments, the 111In-citrate radiopharmaceutical precursor was also shown to afford significant tumor uptake of 111In, but with much poorer tumor-to-background tissue contrast than that obtained with 111In-DTPA- folate. Unconjugated 111In-DTPA showed no tumor affinity. Conclusion: Indium-111-DTPA-folate appears suitable as a radiopharmaceutical for targeting tumor-associated folate receptors.

AB - Indium-111-labeled diethylenetriamine pentaacetic acid (DTPA)-folate was evaluated as a radiopharmaceutical for targeting tumor-associated folate receptors. Methods: Athymic mice were subcutaneously inoculated with ~1.8 x 106 folate receptor-positive KB (human nasopharyngeal carcinoma) cells, yielding 0.2- to 0.6-g tumors in 15 days, at which time 111In-DTPA- folate, 111In-DTPA or 111In-citrate was administered by intravenous injection. Results: The 111In-DTPA-folate conjugate afforded marked tumor- specific 111In deposition in vive using this mouse model. The involvement of the folate receptor in mediating tumor uptake of 111In-DTPA-folate was demonstrated by the blocking of tumor uptake by coadministration of free relic acid (intravenous). The 111In-DTPA-folate also shows folate receptor-mediated uptake and retention in the kidneys, presumably reflecting radiotracer binding to folate receptors of the proximal tubules. In control experiments, the 111In-citrate radiopharmaceutical precursor was also shown to afford significant tumor uptake of 111In, but with much poorer tumor-to-background tissue contrast than that obtained with 111In-DTPA- folate. Unconjugated 111In-DTPA showed no tumor affinity. Conclusion: Indium-111-DTPA-folate appears suitable as a radiopharmaceutical for targeting tumor-associated folate receptors.

KW - Folate receptor

KW - Indium-111-diethylenetriamine pentaacetic acid folate

KW - Tumor targeting

UR - http://www.scopus.com/inward/record.url?scp=0031658693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031658693&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 1579

EP - 1585

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -